Your Job & Career
The newsletters every pharmaceutical professional should be reading
Four industry dailies on trials, regulators and deals, read to you as one short briefing, so an approval or a readout reaches you before the all-hands does.
The best newsletters for pharmaceutical professionals right now are BioPharma Dive Daily DiveFierce Pharma / Fierce Biotech, and Endpoints News. Below is our full 4-newsletter reading list for the role, each one verified against its live signup page, with why it earns a slot, and available as one five-minute daily audio briefing.
The bundle at a glance
| # | Newsletter | Cadence | Cost | Readers | Best for |
|---|---|---|---|---|---|
| 1 | BioPharma Dive Daily Dive | Weekdays | Free | 206k readers | Biopharma professionals who want a free weekday briefing on clinical trial readouts, FDA actions, and dealmaking written for people inside the industry. |
| 2 | Fierce Pharma / Fierce Biotech | Daily | Free | Industry professionals who want comprehensive, high-volume daily coverage of pharma marketing, manufacturing, and biotech financing every weekday morning. | |
| 3 | Endpoints News | daily | Freemium | Drug industry followers who want wire-service speed and real sourcing on drug development, FDA decisions, and dealmaking from a dedicated biopharma newsroom. | |
| 4 | The Readout | Weekdays | Free |
Why niche newsletters, not the same news everyone reads
The general press covers drug news as either a miracle or a scandal, and almost never at the level of an endpoint, a trial design or a label. The industry's own dailies exist for the people who need that detail, so they report the readouts, the agency actions, the licensing deals and the financing that decides whether a program survives. That is the layer at which decisions in this industry are actually made.
What the job really takes
Working in pharma means living on timelines you do not fully control. A program moves through preclinical work, trial phases, regulatory review and launch, and at every stage the value of years of work can turn on a single readout or an agency decision. Whether you sit in clinical development, regulatory affairs, commercial or manufacturing, your planning depends on external events: what a competitor reported, how an agency treated a similar application, which indication a rival abandoned, and what the payers did about a comparable launch.
How to stand out
The people who move quickly in this industry are fluent in the competitive landscape beyond their own molecule. Knowing that a rival's phase two readout missed on the secondary endpoint, or that an agency asked for an additional study in the same class, changes how you brief a team and how credible you sound in front of leadership. That fluency is also what makes cross-functional work possible, because commercial, clinical and regulatory colleagues all need the same shared picture of the field.
Where this bundle comes from
Every newsletter in your bundle comes from the category that matters most in this job:
- 4Biotech & Pharma →The entire bundle is the industry's own trade press, because trial readouts, regulatory actions and licensing deals are reported properly nowhere else.
Your 4-newsletter bundle
- 1
Why pharmaceutical professionals read itIndustry Dive's free weekday briefing tracking clinical trials, regulatory actions and dealmaking for people inside the industry, read by more than 200,000 of them. It is the most complete daily view of the sector and the natural anchor here.
BioPharma Dive is Industry Dive's free weekday briefing on biotech and pharma: clinical trial readouts, FDA actions, and dealmaking, written for people inside the industry. Its advertising page claims 206,000 newsletter subscribers. The accessible end of the biopharma trade press.
- 2
Why pharmaceutical professionals read itThe long-running flagship daily on pharma and biotech industry news. Its commercial coverage, on launches, marketing and manufacturing, runs deeper than the science-first sources, which is why it earns a slot alongside them.
Fierce Pharma and Fierce Biotech are the long-running flagship dailies of the drug-industry trade press, covering pharma marketing, manufacturing, clinical results, and biotech financing each weekday morning. High volume and comprehensive. The default inbox presence for industry professionals.
- 3
Why pharmaceutical professionals read itA daily on drug development, agency decisions, deals and the business of medicine, written for an industry audience. It tends to carry the reporting on financing and strategy that determines which programs continue.
Endpoints News is a dedicated biopharma newsroom whose daily emails track drug development, FDA decisions, and dealmaking with wire-service speed and real sourcing. The core newsletters are free; deeper reporting sits behind an Endpoints subscription. A must-follow for anyone serious about the drug industry.
- 4
Why pharmaceutical professionals read itSTAT's free weekday morning newsletter on the science, politics and money driving biotech, from reporters who cover the field full time. It is the strongest of these on the science itself and on how policy will treat it.
The Readout lands every weekday morning with a rundown of biotech news: clinical readouts, FDA decisions, deals, and market moves, linking to STAT's reporting. The signup page currently credits reporters Meghana Keshavan and Elaine Chen. The newsletter itself is free, though some linked stories sit behind the STAT+ paywall.
BioPharma Dive reaches over 200,000 industry readers each weekday and The Readout puts STAT's biotech desk in the same inboxes as your competitors' teams. When a readout drops, the people across the street have already read three takes on what it means for your program.
Start the Pharmaceutical Professionals bundle →Trusted by the people ahead of you · one briefing · free to start
Questions
- What newsletters should a pharmaceutical professional read?
- Four industry dailies cover it: BioPharma Dive for the complete weekday view of trials and regulatory actions, Fierce Pharma for commercial and manufacturing depth, Endpoints News for financing and strategy, and The Readout for the science and policy. Hark News reads all four to you as one daily briefing.
- Which newsletter is best for FDA and regulatory news?
- BioPharma Dive covers agency actions most systematically as part of its weekday briefing, and The Readout is the best on how politics and policy are likely to shape a decision. Reading them together gives you both the action and the context around it.
- Is this bundle useful for biotech as well as large pharma?
- Yes. Three of these four cover biotech and pharma as one industry, because the science, the financing and the regulators are shared. The emphasis here leans slightly commercial, which is what distinguishes it from a research-first reading list.
- Do I need all four, or is there too much overlap?
- There is real overlap on the biggest stories, which is unavoidable when four dailies cover one industry. The value is in the divergence: each has beats and sources the others lack, and hearing them as one briefing means the duplication costs you seconds rather than four separate reads.
- Are these newsletters free?
- Yes, all four are free to subscribe to, though their publishers sell deeper subscription products alongside the free emails.
- How long does this briefing take?
- About five minutes on the base plan. Four industry dailies would otherwise be the first twenty minutes of your morning, most of it spent recognizing the same readout described four ways.
- Can I add my company's internal digests?
- Anything that arrives at your Hark address becomes part of your briefing, so an internal or association digest you already receive by email can be included alongside these.